Chemotherapy and Immunity - Pharmacist Digest

Opinion: Making the promise of monoclonal antibody therapies available to all

STAT

MAY 8, 2024

Often overlooked or sidelined by newsmakers and policymakers, these individuals continue to confront a heightened risk of severe illness or death due to their compromised immune systems, while society largely adjusts to life with the virus.

Chemotherapy

STAT+: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases

STAT

NOVEMBER 29, 2023

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation.

Chemotherapy

STAT+: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease

STAT

DECEMBER 12, 2023

This approach has been around for decades but required patients to have a well-matched donor and endure a hefty dose of chemotherapy, ruling out transplant as an option for the vast majority of patients.

Chemotherapy

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT

JUNE 6, 2023

Novocure’s study achieved its primary goal and showed a survival benefit for patients with lung cancer that progressed following initial chemotherapy.

Chemotherapy

Dr. Reddy’s launches Toripalimab under the brand name Zytorvi in India

Express Pharma

NOVEMBER 28, 2024

The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Chemotherapy

STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more

STAT

APRIL 11, 2024

These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills. Continue to STAT+ to read the full story…

Chemotherapy

NICE recommends combo therapy for gastroesophageal cancer

European Pharmaceutical Review

NOVEMBER 24, 2022

Nivolumab (Opdivo), together with chemotherapy has been recommended in the National Institute for Health and Care Excellence NICE final draft guidance for untreated HER2-negative, advanced or metastatic gastric, gastroesophageal junction (GEJ) or oesophageal adenocarcinoma where tumours express programmed death-1 receptor (PD-L1).

Chemotherapy

Immunotherapy to become standard treatment for infants with ALL

European Pharmaceutical Review

APRIL 27, 2023

Blinatumomab significantly improved survival, with the rate increasing from 66 percent to 93 percent, compared to individuals just given prior chemotherapy. Monoclonal antibody ( mAb ) blinatumomab binds to leukaemia cells on one side and to immune cells on the other side.

Chemotherapy

Novel vaccine delivers significant survival in lung cancer trial

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. months for chemotherapy. The overall survival rate at one year with Tedopi was 44.4 percent versus 27.5

Vaccines

Vaccines Chemotherapy Immunity Immunization

New therapy harnesses patients' blood cells to fight tumors

World Pharma News

APRIL 10, 2023

The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma.

Chemotherapy

Opdivo and chemotherapy combo increases survival in lung cancer patients

pharmaphorum

NOVEMBER 9, 2021

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system.

Chemotherapy

Serplulimab increases survival in small cell lung cancer patients

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).

Chemotherapy

Merck discontinues Phase 3 trial for lung cancer combo drug

Express Pharma

AUGUST 8, 2024

Additionally, when compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm experienced a higher rate of adverse events (AEs) and immune-related AEs. At a pre-planned analysis, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria.

Chemotherapy

J&J’s EGFR-mutated advanced lung cancer treatment: amivantamab-vmjw plus lazertinib gains FDA approval

Express Pharma

AUGUST 22, 2024

Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) is approved in the US as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. The chemotherapy-free regimen showed progression-free survival versus osimertinib.

Chemotherapy

Intratumoural viral delivery improves glioblastoma survival

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunity

Nivolumab plus chemo provides one-year PFS in 94 percent lymphoma patients

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

JANUARY 26, 2023

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy

At ESMO, three studies show promise of antibody-drug conjugates in breast cancer

pharmaphorum

MAY 30, 2022

“An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. So there’s a Trojan horse-like mechanism to deliver chemotherapy right to the cancer cell.”. While directed chemotherapy isn’t totally free of side effects, it reduces them.

Chemotherapy

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.

Vaccines

Vaccines Bioethics Immunity Immunization

SABCS 2024: Using Tumor Immune Profiles to Guide Neoadjuvant Therapy in Young Breast Cancer Patients

Pharmacy Times

DECEMBER 11, 2024

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Immunity

A history of blood cancer treatment

pharmaphorum

SEPTEMBER 13, 2022

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 1942 – Chemotherapy moves from trenches to treatment . 1942 – Chemotherapy moves from trenches to treatment . 1907 – The magic bullet of immunotherapy.

Chemotherapy

Chemotherapy Immunity Immunization Documentation

Oncolytic viruses: past and present

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed.

Immunity

Immunity Immunization Chemotherapy Packaging

ESMO: TIL therapy improves on Yervoy in melanoma trial

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunity

Immunity Immunization Chemotherapy Hospitals

BMS strikes back against Merck in EU oesophageal cancer market

pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunity

Immunity Immunization Chemotherapy Pharmaceutical Companies

The end-of-life care conundrum

pharmaphorum

JANUARY 3, 2023

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Chemotherapy

NICE recommends first CAR-T cell therapy on NHS in England

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.

Chemotherapy

Neoadjuvant Atezolizumab Plus Epirubicin Shows Safety, Efficacy in Treatment of HER2+ Early Breast Cancer

Pharmacy Times

JANUARY 24, 2025

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Chemotherapy

Immunotherapy Makes Major Strides for First-line Treatment of Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Pharmacy Times

DECEMBER 19, 2022

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Chemotherapy

AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunity

Imugene HER2 vaccine hits target in stomach cancer trial

pharmaphorum

JULY 6, 2021

The interim readout from the 39-patient HERIZON trial found 50% of patients treated with the HER-Vaxx (IMU-131) vaccine on top of chemotherapy achieved a partial response or better, compared to 29% of patients given only chemo.

Vaccines

Vaccines Chemotherapy Immunity Immunization

Trial highlights potential next-gen biologic for lung cancer

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. New clinical data has shown a potential best-in-class next-generation antibody-drug conjugate (ADC) can offer promising response rates in extensive-stage small cell lung cancer.

Chemotherapy

Chemotherapy Compounding Immunity Immunization

Could personalised mRNA vaccine be first for cancer?

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines

Vaccines Immunity Immunization Chemotherapy

Advancements in Veterinary Oncology—What You Need to Know

epicur

JULY 12, 2023

Chemo Blister Packs For safer, more convenient treatment Epicur® chemotherapy tablets are manufactured in our FDA Registered Outsourcing Facility following cGMP. Personalized care throughout the treatment process We know side effects of chemotherapy treatment can be difficult for your patients and their owners. Targeted drug therapy.

Immunity

Immunity Immunization Chemotherapy Vaccines

FDA approves innovative engineered cell therapy

European Pharmaceutical Review

AUGUST 2, 2024

The approval means TECELRA is indicated for individuals who: have received prior chemotherapy are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive have a tumour that expresses the MAGE-A4-antigen The FDA’s decision was based on results of the Phase II SPEARHEAD-1 (Cohort 1) trial.

Chemotherapy

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunity

Novartis extends Kaiku digital patient monitoring partnership

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy

FDA Fast Track designation for photodynamic cancer therapy

European Pharmaceutical Review

NOVEMBER 28, 2022

The drug was evaluated in four Phase II/III clinical trials in patients previously given chemotherapy and/or failed radiation therapy. If marketed, REM-001, produced by Kintara Therapeutics, could be a potential therapy for advanced breast cancer patients who have limited treatment options.

Chemotherapy

Chemotherapy Immunity Immunization Drug Development

FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

LifeProNow

APRIL 19, 2023

The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). director of the FDA’s Center for Biologics Evaluation and Research.

Adverse Reactions

Adverse Reactions Chemotherapy Labelling Immunity

Advancing microbiome innovation

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunity

Immunity Immunization Chemotherapy Diabetes

Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData

Express Pharma

FEBRUARY 21, 2024

There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). GlobalData estimates the drug to earn $3.12 billion by 2029. “ Notably, the non-squamous patient subset had a median PFS of 5.6 months vs. 3.7

Chemotherapy

Chemotherapy Labelling Immunity Immunization

Company profile: NeoImmuneTech

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. About the interviewee.

Immunity

Immunity Immunization Chemotherapy Compounding

Advancing cell therapies – ?? T cells and the combination factor

European Pharmaceutical Review

JULY 13, 2022

Our work is establishing whether it is possible to use allogeneic innate immune cells from a healthy donor to support the immune system of a person with cancer in combatting the condition. T cells are the first line of defence in the immune system to eradicate diseases. such as a chimeric antigen receptor (CAR). In response, ??

Immunity